BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wolsk E, Kaye D, Borlaug BA, Burkhoff D, Kitzman DW, Komtebedde J, Lam CSP, Ponikowski P, Shah SJ, Gustafsson F. Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2018;20:715-22. [PMID: 28949052 DOI: 10.1002/ejhf.976] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
Number Citing Articles
1 Pierce JD, Shen Q, Mahoney DE, Rahman F, Krueger KJ, Diaz FJ, Clark L, Smith C, Vacek J, Hiebert JB. Effects of Ubiquinol and/or D-ribose in Patients With Heart Failure With Preserved Ejection Fraction. Am J Cardiol 2022;176:79-88. [PMID: 35644694 DOI: 10.1016/j.amjcard.2022.04.031] [Reference Citation Analysis]
2 Lauder L, Pereira TV, Degenhardt MC, Ewen S, Kulenthiran S, Coats AJS, Böhm M, Anker SD, da Costa BR, Mahfoud F. Feasibility and efficacy of transcatheter interatrial shunt devices for chronic heart failure: a systematic review and meta-analysis. Eur J Heart Fail 2021. [PMID: 34628706 DOI: 10.1002/ejhf.2360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Samuel TJ, Beaudry R, Sarma S, Zaha V, Haykowsky MJ, Nelson MD. Diastolic Stress Testing Along the Heart Failure Continuum. Curr Heart Fail Rep 2018;15:332-9. [PMID: 30171472 DOI: 10.1007/s11897-018-0409-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
4 Kaye DM, Petrie MC, McKenzie S, Hasenfuβ G, Malek F, Post M, Doughty RN, Trochu JN, Gustafsson F, Lang I, Kolodziej A, Westenfeld R, Penicka M, Rosenberg M, Hausleiter J, Raake P, Jondeau G, Bergmann MW, Spelman T, Aytug H, Ponikowski P, Hayward C; REDUCE LAP-HF study investigators. Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. ESC Heart Fail 2019;6:62-9. [PMID: 30311437 DOI: 10.1002/ehf2.12350] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
5 Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur J Heart Fail 2020;22:391-412. [PMID: 32133741 DOI: 10.1002/ejhf.1741] [Cited by in Crossref: 56] [Cited by in F6Publishing: 44] [Article Influence: 28.0] [Reference Citation Analysis]
6 Tomasoni D, Adamo M, Lombardi CM, Metra M. Highlights in heart failure. ESC Heart Fail 2019;6:1105-27. [PMID: 31997538 DOI: 10.1002/ehf2.12555] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
7 Stavrakis S, Elkholey K, Morris L, Niewiadomska M, Asad ZUA, Humphrey MB. Neuromodulation of Inflammation to Treat Heart Failure With Preserved Ejection Fraction: A Pilot Randomized Clinical Trial. J Am Heart Assoc 2022;:e023582. [PMID: 35023349 DOI: 10.1161/JAHA.121.023582] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Jürgens M, Schou M, Hasbak P, Kjær A, Wolsk E, Zerahn B, Wiberg M, Brandt NH, Gæde PH, Rossing P, Faber J, Inzucchi S, Gustafsson F, Kistorp CM. Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). BMJ Open 2019;9:e029098. [PMID: 31780586 DOI: 10.1136/bmjopen-2019-029098] [Reference Citation Analysis]
9 Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J 2019;40:3297-317. [PMID: 31504452 DOI: 10.1093/eurheartj/ehz641] [Cited by in Crossref: 268] [Cited by in F6Publishing: 199] [Article Influence: 134.0] [Reference Citation Analysis]
10 Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA. The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respiratory Medicine 2022;196:106801. [DOI: 10.1016/j.rmed.2022.106801] [Reference Citation Analysis]
11 Kelly JP, DeVore AD. Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home? Eur J Heart Fail 2018;20:723-4. [PMID: 29082577 DOI: 10.1002/ejhf.1041] [Reference Citation Analysis]
12 Gupta A, Bailey SR. Update on Devices for Diastolic Dysfunction: Options for a No Option Condition? Curr Cardiol Rep 2018;20. [DOI: 10.1007/s11886-018-1027-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
13 Crespo-leiro MG, Metra M, Lund LH, Milicic D, Costanzo MR, Filippatos G, Gustafsson F, Tsui S, Barge-caballero E, De Jonge N, Frigerio M, Hamdan R, Hasin T, Hülsmann M, Nalbantgil S, Potena L, Bauersachs J, Gkouziouta A, Ruhparwar A, Ristic AD, Straburzynska-migaj E, Mcdonagh T, Seferovic P, Ruschitzka F. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology: Advanced heart failure: HFA position statement. Eur J Heart Fail 2018;20:1505-35. [DOI: 10.1002/ejhf.1236] [Cited by in Crossref: 217] [Cited by in F6Publishing: 145] [Article Influence: 54.3] [Reference Citation Analysis]
14 Miyagi C, Miyamoto T, Karimov JH, Starling RC, Fukamachi K. Device-based treatment options for heart failure with preserved ejection fraction. Heart Fail Rev 2021;26:749-62. [PMID: 33432418 DOI: 10.1007/s10741-020-10067-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
15 Wolsk E, Kaye DM, Komtebedde J, Shah SJ, Borlaug BA, Burkhoff D, Kitzman DW, Cleland JG, Hasenfuß G, Hassager C, Møller JE, Gustafsson F. Determinants and consequences of heart rate and stroke volume response to exercise in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2021;23:754-64. [PMID: 33686716 DOI: 10.1002/ejhf.2146] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Nashawi M, Sheikh O, Battisha A, Mir M, Chilton R. Beyond the myocardium? SGLT2 inhibitors target peripheral components of reduced oxygen flux in the diabetic patient with heart failure with preserved ejection fraction. Heart Fail Rev 2020. [PMID: 32583230 DOI: 10.1007/s10741-020-09996-y] [Reference Citation Analysis]
17 Normand C, Kaye DM, Povsic TJ, Dickstein K. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet 2019;393:1045-55. [PMID: 30860030 DOI: 10.1016/S0140-6736(18)32216-5] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
18 Piepoli MF, Spoletini I, Rosano G. Monitoring functional capacity in heart failure. Eur Heart J Suppl 2019;21:M9-M12. [PMID: 31908608 DOI: 10.1093/eurheartj/suz216] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Emani S, Burkhoff D, Lilly SM. Interatrial shunt devices for the treatment of heart failure. Trends in Cardiovascular Medicine 2020. [DOI: 10.1016/j.tcm.2020.09.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Litwin SE, Zile MR. The Vexing Problem of HFpEF Therapeutics: Inching Toward Success. JACC Heart Fail 2021;9:371-3. [PMID: 33926730 DOI: 10.1016/j.jchf.2021.02.005] [Reference Citation Analysis]
21 Lewis GD, Houstis NE. The Upsurge in Exercise Hemodynamic Measurements in Heart Failure With Preserved Ejection Fraction. JACC Heart Fail 2019;7:333-5. [PMID: 30922509 DOI: 10.1016/j.jchf.2019.02.003] [Reference Citation Analysis]
22 Kaye DM, Nanayakkara S. Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction. Front Cardiovasc Med 2019;6:143. [PMID: 31620452 DOI: 10.3389/fcvm.2019.00143] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
23 Yi T, Li M, Fan F, Qiu L, Wang Z, Weng H, Shang X, Zhang C, Ma W, Zhang Y, Huo Y. Haemodynamic changes of interatrial shunting devices for heart failure: a systematic review and meta-analysis. ESC Heart Fail 2022. [PMID: 35322588 DOI: 10.1002/ehf2.13911] [Reference Citation Analysis]
24 Tomasoni D, Adamo M, Anker MS, von Haehling S, Coats AJS, Metra M. Heart failure in the last year: progress and perspective. ESC Heart Fail. 2020;. [PMID: 33277825 DOI: 10.1002/ehf2.13124] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
25 Wolsk E, Gustafsson F. When Making Your Bed Feels Like Running a Marathon: Understanding Exercise Limitation in Heart Failure. Circ Heart Fail 2020;13:e007993. [PMID: 33201751 DOI: 10.1161/CIRCHEARTFAILURE.120.007993] [Reference Citation Analysis]
26 Nayor M, Houstis NE, Namasivayam M, Rouvina J, Hardin C, Shah RV, Ho JE, Malhotra R, Lewis GD. Impaired Exercise Tolerance in Heart Failure With Preserved Ejection Fraction: Quantification of Multiorgan System Reserve Capacity. JACC Heart Fail 2020;8:605-17. [PMID: 32535122 DOI: 10.1016/j.jchf.2020.03.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
27 Stephens-Shields AJ, Farrar JT, Ellenberg SS, Storer TW, Gill TM, Basaria S, Pahor M, Cauley JA, Ensrud KE, Preston P, Cella D, Snyder PJ, Bhasin S. Clinically Important Differences for Mobility Measures Derived from the Testosterone Trials. J Am Geriatr Soc 2021;69:517-23. [PMID: 33210287 DOI: 10.1111/jgs.16942] [Reference Citation Analysis]